Navigation Links
Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
Date:1/15/2008

of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, there is a risk that the transaction referred to in this press release may be delayed or may not ultimately close if certain conditions set forth in the Step-Up Equity Financing Agreement are not satisfied. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian or Susan Callahan

T: 206.272.4343 or 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Follow us on ... nanomaterial with diameter ranging between 2 to 10 ... nanophotonics materials market. The unique electroluminescent, photoluminescent, photo-physical, ... quantum confinement effect render the nanoparticles versatile and ... scientific, technological, and commercial applications. A host of ...
(Date:5/6/2015)... 6, 2015  Oxis Biotech, Inc. (OXIS), a wholly ... announced today that Cassian Yee , M.D., Professor, ... at the University of Texas MD Anderson Cancer Center ... Professor, Department of Immunology, Division of Cancer Medicine, and ... Research at the University of Texas MD Anderson Cancer ...
(Date:5/6/2015)... 2015 Dr Jaspreet Singh , Senior ... deliver a speech at the 2015 Asian Starch Conference, to ... Expo Center.  , ... the topic: ,Potato Starch: A Potential Source for the ... Co-editor of a 528 page text book entitled ...
(Date:5/5/2015)... SAN DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose ... "Company") today reported financial results for the three months ... Unless specified otherwise, all amounts are in Canadian dollars. ... changed its fiscal year end from May 31 to ... current interim period being reported is for the three ...
Breaking Biology Technology:Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... ... ensure future crisis prevented. , ... Davos-Klosters, Switzerland (Vocus) Jan. 29, 2010 -- Agriculture is a game-changer that ... such as civil unrest, DuPont Chair and CEO Ellen Kullman told attendees ...
... , Data Demonstrating a 35% Overall Response ... in Patients with Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to ... Issue of the Journal of Clinical Cancer Research , ... Zentaris Inc. (Nasdaq: AEZS ; TSX: AEZ) (the ...
... , Jan. 28 RSB Spine, LLC, today ... the company,s 510(k) application to permit the marketing of its ... Executive Officer John A. Redmond said: "We are ... distributors two additional products to offer customers seeking greater options ...
Cached Biology Technology:DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... across the United States and Russia are departing July 2 ... program, known as The Polaris Project, is training future leaders ... the impacts of climate change. Dr. R. ... Center and director of the Polaris Project, says, "The Arctic ...
... researchers have been able to identify genetic predictors of the ... Cathy Allen, from the Rotunda Hospital, Dublin, Ireland, told the ... and Embryology today (Wednesday 1 July) that her research would ... for others. Previous work in this area has looked ...
... of forest biotechnology to help address significant social and ... rigid opposition of some groups and regulations that effectively ... argue in a new report. Steps must be ... modified trees on a scientific, case-by-case basis, and is ...
Cached Biology News:International team of students and scientists on month-long field course in Siberian Arctic 2International team of students and scientists on month-long field course in Siberian Arctic 3Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3Anti-biotech groups obstruct forest biotechnology 2Anti-biotech groups obstruct forest biotechnology 3